Issue: November 2018
September 20, 2018
5 min read
Save

Organized CRC Program Significantly Increases Screening Rates

Issue: November 2018
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Theodore Levin, MD
Theodore R. Levin
Douglas Corley, MD, PhD
Douglas A. Corley

The implementation of an organized screening program of annual fecal immunochemical tests combined with colonoscopy demonstrated a significant, and rapid, increase of colorectal cancer screening participation, according to results of a dynamic cohort of health plan members at an institution.

The results also demonstrated that as colorectal screening participation increased over a 15-year period, cancer mortality decreased more than 50% during that time.

“We started colorectal cancer screening with flexible sigmoidoscopy in 1994 and were doing large volumes of procedures,” Theodore R. Levin, MD, chief of Gastroenterology at Kaiser Permanente Medical Center, Walnut Creek, and a research scientist at Kaiser Permanente Northern California, told Healio Gastroenterology and Liver Disease. “Yet when the National Committee on Quality Assurance incorporated colorectal cancer screening into its Health Care Effectiveness Data and Information Set measure in 2004 our performance was below what we wanted to provide to our patients.”

Douglas A. Corley, MD, PhD , a research scientist at Kaiser Permanente Northern California and study co-author, said that after seeing encouraging results from research evaluating fecal immunochemical tests (FIT), the Kaiser network decided to implement the tests to try to increase screening participation.

“We expected that sending FIT kits through the mail would be a great way to reach patients who may have declined screening with flexible sigmoidoscopy or were not coming into the office often enough to be reminded to be screened,” Corley told Healio Gastroenterology and Liver Disease. “We saw an initial rapid uptake of screening and our rates increased to about 65%.”

Levin, Corley and colleagues used a dynamic cohort of Kaiser Permanente Northern California health plan members from 2000 to 2015 to evaluate if an organized colorectal cancer screening program could achieve and maintain the 80% or higher screening target proposed by various organizations.

Additionally, the researchers wanted to determine if changes in screening rates would correlate to changes in colorectal cancer incidence and mortality.

Prior to 2006, colorectal cancer screening within the cohort was predominantly performed using sigmoidoscopy and gFOBT and was always performed by physician request, according to the results.

Screening transitioned region-wide in 2007 to direct-to-patient annual FIT outreach for members aged 60 to 69 years who were not screening up-to-date by other methods and was expanded to members aged 51 to 75 years in 2008.

Colonoscopy did remain an option during this period.

The researchers sampled patient characteristics from 2000, 2008 and 2015. During each year, patients were predominantly aged 51 to 64 years (68.5%-74%), female (52.5%-53%) and non-Hispanic white (58.4%-64.4%).

PAGE BREAK

From 2000 to 2005, screening participation was from 39.7% to 40.5%. However, participation began to rise as FIT was being implemented.

Members up-to-date with screening significantly increased from 38.9% in 2000, to 82.7% in 2015 (P < .01).

Initially, age-adjusted colorectal cancer incidence rates increased from 95.8 cases/100,000 (95% CI; 88.1-103.4) in 2000 to a high of 117.8 cases/100,000 (95% CI; 110.4-125.2; P < .01) in 2008.

However, overall age-adjusted colorectal cancer incidence rates decreased 25.5% between 2000 and 2015 (P < .01).

Age-adjusted incidence-based mortality rates decreased by 52.4%, from 30.9 deaths/100,000 (95% CI; 26.6-35.3) in 2000 to 14.7/100,000 (95% CI; 12.3-17.1) in 2015.

“The implications of these results are that a meaningful impact [can be made] on colorectal cancer incidence and mortality by increasing screening rates using a combination of FIT and colonoscopy,” Levin said. “This can be achieved in the real world and not just in clinical trials.”

Corley did acknowledge that while their approach is a good start, they did have some structural advantages.

“[We had] an integrated health care delivery system with primary care and specialists working together, a pre-paid financial model giving us more flexibility with how we use resources than a traditional fee for service system, and a comprehensive integrated electronic record providing real time information on who is up to date with screening,” he said. “[But] even without those advantages, everyone can start by offering FIT screening as an alternative to colonoscopy. The first step, though, is to measure your population and see who needs to be screened.” – by Ryan McDonald

Disclosures: The researchers report no relevant financial disclosures.